61460 Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices 

comprise adeno-associated virus 

serotype 5 (AAV5). AAV5 is a singlestranded DNA virus of either plus or 

minus polarity which, like other AAV 

serotypes (e.g., AAV4, AAV2) requires a 

helper virus for replication. AAV type 2 

has the interesting and potentially 

useful ability to integrate into human 

chromosome 19 q 13.3-q ter. This 

activity is dependent on the nonstructural, Rep, proteins of AAV2. The 

Rep proteins of AAV types 2 and 5 are 

dissimilar and are not able to substitute 

in DNA replication of the heterologous 

serotype. 

AAV5 offers several advantages which 

make it attractive for use in gene 

therapy: 1. Increased production (10–50 

fold greater than AAV2); 2. distinct 

integration locus when compared to 

AAV2; 3. Rep protein and ITR regions 

do not complement other AAV 

serotypes; and 4. appears to utilize 

different cell surface attachment 

molecules than those of AAV type 2. 

In addition to licensing, the 

technology may be available for further 

development through collaborative 

research opportunities with the 

inventors. 

The Use of Nitroxides in the 

Prophylactic and Therapeutic 

Treatment of Cancer Due to Genetic 

Defects 

James Mitchell, Angelo Russo, Anne 

Deluca and Murali Cherukuri (NCI). 

U.S. Patent Application No. 09/424,519 

filed 03 Mar 2000, claiming priority to 

27 May 1997 (HHS Reference No. E–

167–1997/0–US–07). 

Licensing Contact: George Pipia; 301/ 

435–5560; pipiag@mail.nih.gov. 

The invention is a method for 

preventing or treating cancer, especially 

cancers associated with defects in the 

p53 gene. This gene is generally 

considered to be a tumor-suppressor 

gene, and in a large percentage of 

malignancies including pancreatic, 

colon, lung, and breast, the gene is 

found to be inactive in the cancer. It is 

believed that many individuals have 

genetic defects in p53 predisposing 

them to cancer. 

The invention involves the use of 

certain nitroxides as agents to slow the 

appearance or progression of tumors 

associated with p53 knockout. Thus, 

these compounds could serve as 

preventative agents for people 

predisposed to cancer, or as therapeutic 

agents for certain cancers. As nitroxides 

have already been identified as 

antioxidants, such agents could become 

part of a cancer prevention and antiaging regimen. A new method of use for 

these compounds now include their use 

in imaging, which correlates functional 

information about the tumor with 

magnetic resonance imaging data. 

Dated: October 13, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–21118 Filed 10–21–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel PAR–04–

020: Small Grants for Behavioral Research in 

Cancer Control 

Date: November 9, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washington 

Boulevard, Gaithersburg, MD 20878 

Contact Person: C. Michael Kerwin, PhD, 

MPH, Scientific Review Administrator, 

Special Review and Logistics Branch, 

Division of Extramural Activities, National 

Cancer Institute, National Institutes of 

Health, 6116 Executive Boulevard, Room 

8057, MSC 8329, Bethesda, MD 20892–8329, 

301–496–7421, kerwinm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 13, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21124 Filed 10–21–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Large-Scale Genotyping of NHLBI Cohorts 

Date: October 20, 2005. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate contract 

proposals 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Valerie L Prenger, PhD, 

Chief, Review Branch, Division of Extramural 

Affairs, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, MSC 7924, 

Room 7214, Bethesda, MD 20892–7924, 301–

435–0270, prengerv@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

October 24, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21133 Filed 10–21–05; 8:45 am] 

BILLING CODE 4140–01–M